HIV Needle Stick Risk Assessment Stratification Protocol (RASP)
ورودیهای بالینی بیمار
پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.
- Definitely Indicated0–1000
- Recommended1001–10000
- Optional10001–100000
- Not Indicated100001–999999999
The HIV Needle Stick Risk Assessment Stratification Protocol (RASP) calculates predicting invasive bacterial infection probability and quantifying systemic host response to sepsis. Key inputs include source population. Scores guide administering empiric broad-spectrum antimicrobial regimens, infectious source control, and isolation protocols. Routine clinical application promotes standardized evidence-based patient management.
Clinical Guidelines & Evidence
Quantifies HIV exposure risk by source and exposure type to guide post-exposure prophylaxis (PEP) decisions following needle stick injuries or other potential HIV exposures.
Clinical Indication
The HIV Needle Stick Risk Assessment Stratification Protocol (RASP) is indicated for bedside clinical practice to support Quantifies HIV exposure risk by source and exposure type to guide post-exposure prophylaxis (PEP) decisions following needle stick injuries or other potential HIV exposures.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.
Target Population
Target population comprises Patients presenting with suspected sepsis, meningitis, pneumonia, COVID-19, opportunistic infections, or fever of unknown origin. Clinical application is indicated across Infectious disease services, septic shock bays, febrile illness clinics, and isolation units.
Limitations & Contraindications
Timely administration of empiric antibiotic therapy in suspected septic shock must never be delayed for score tabulation.
Clinical Pearls & Action Plan
Blood and site-specific microbiological cultures should be secured prior to administering broad-spectrum antimicrobials.
Basic risk = 1 / (Source population × Inoculum type × Method of transmission); Total risk (1 in X) = Basic risk × Volume of inoculum
Input Parameters
| Name | Type | Required | Description |
|---|---|---|---|
| source_population | string | Yes | HIV status and clinical condition of source patient |
| inoculum_type | string | Yes | Type of body fluid involved in exposure |
| transmission_method | string | Yes | Method of exposure/transmission route |
| inoculum_volume | string | Yes | Volume of inoculum/exposure |
Score Interpretation & Guidance
| Range | Stage | Description |
|---|---|---|
| 0–1000 | Definitely Indicated | Risk ≥1/1000 |
| 1001–10000 | Recommended | Risk 1/1001-1/10000 |
| 10001–100000 | Optional | Risk 1/10001-1/100000 |
| 100001–999999999 | Not Indicated | Risk ≤1/100000 |
Evidence-Based References (EBM)
- Vertesi L. Risk Assessment Stratification Protocol (RASP) to help patients decide on the use of postexposure prophylaxis for HIV exposure. CJEM. 2003 Jan;5(1):46-8.
- Panlilio AL, Cardo DM, Grohskopf LA, Heneine W, Ross CS; U.S. Public Health Service. Updated U.S. Public Health Service guidelines for the management of occupational exposures to HIV and recommendations for postexposure prophylaxis. MMWR Recomm Rep. 2005 Sep 30;54(RR-9):1-17.
- Cardo DM, Culver DH, Ciesielski CA, Srivastava PU, Marcus R, Abiteboul D, et al. A case-control study of HIV seroconversion in health care workers after percutaneous exposure. Centers for Disease Control and Prevention Needlestick Surveillance Group. N Engl J Med. 1997 Nov 20;337(21):1485-90.